TOP-5 studies on obesity, diabetes, and insulin resistance from 13.10.2026 - 20.10.2026
Body weight after a multi-component lifestyle intervention in older adults at risk of dementia - post-hoc analysis of the AgeWell.de study; Efficacy and safety of imeglimin hydrochloride in metabolic dysfunction associated with liver steatosis in patients with type 2 diabetes: a single-center, open-label phase 2 study (IMELD study); Diabetes medications in development; Physical exercise, dietary, and combined interventions (exercise and diet) for metabolic syndrome: a Bayesian network and component network meta-analysis of randomized controlled trials; Glucose-lowering therapies in sarcopenia associated with type 2 diabetes: mechanisms, clinical data, and a muscle-centered concept.
5. Body weight changes after a multi-component lifestyle intervention in older adults at risk of dementia - post-hoc analysis of the AgeWell.de study.
About the work.
Changes in body weight in older adults with overweight or obesity after a multi-component intervention were analyzed within the AgeWell.de trial. The focus was on the relationship between group allocation and changes in body weight, as well as the role of motivation and confidence in weight loss.
Results.
Group allocation was not associated with changes in body weight at 24 months. Older age and higher education levels were associated with lower body weight, while higher baseline weight predicted greater weight at follow-up. Motivation and confidence levels for weight loss remained high but stable in both groups.
4. Efficacy and safety of imeglimin hydrochloride in metabolic dysfunction associated with liver steatosis in patients with type 2 diabetes: a single-center, open-label phase 2 study (IMELD study).
About the work.
The study evaluated the efficacy and safety of 24 weeks of imeglimin treatment in patients with metabolic dysfunction associated with liver steatosis and type 2 diabetes. Patients received 1000 mg of imeglimin twice daily.
Results.
The median ALT level significantly decreased from 56.00 (47.00-75.00) U/L at baseline to 34.00 (29.00-51.00) U/L at 24 weeks (P < 0.001).
3. Diabetes medications in development.
About the work.
New therapeutic approaches to diabetes treatment are discussed, including multi-target drugs and incretin agonists. The focus is on various classes of antidiabetic medications and their impact on metabolic pathways.
Results.
Today, new insulin sensitizers modify metabolic pathways, providing higher energy with fewer side effects. Adjunctive therapies for type 1 diabetes improve glucose control and reduce the risk of hypoglycemia. The diabetes pipeline includes promising developments that could transform the therapeutic landscape.
2. Physical exercise, dietary, and combined interventions (exercise and diet) for metabolic syndrome: a Bayesian network and component network meta-analysis of randomized controlled trials.
About the work.
The aim of the study was to compare the effects of structured interventions in physical exercise, diet, and their combination on components of metabolic syndrome in overweight or obese adults. The study included 78 randomized controlled trials.